Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)Zurina Cinza-Estévez, Y. RodriguezGuevara, Cristina Olimpia Chávez-Chong et al.|EClinicalMedicine|2023Cited by 6
Evaluation of the Effect and Safety of HeberFERON vs Heberon Alpha in Patients Infected with Corona Virus SARS-CoV-2 (Study ESPERANZA/HOPE): Study Protocol for a Randomized Controlled Trial.Bello-Rivero Iraldo, Gerardo Guillén, Francisco Hernández‐Bernal et al.|Research Square|2020Cited by 2
A combination treatment of IFN-α2b and IFN-γ accelerates viral clearance and control inflammatory response in COVID-19: Preliminary results of a randomized controlled trialIdelsis Esquivel-Moynelo, Iraldo Bello Rivero, Jesus Perez-Escribano et al.|Annals of Antivirals and Antiretrovirals|2021Cited by 2
Phase II randomized controlled trial to evaluate the efficacy and safety of HeberFERON versus Heberon alpha R in symptomatic or asymptomatic patients infected with the SARS-CoV-2 (Study ESPERANZA/HOPE).Bello-Rivero Iraldo, Gerardo Guillén, Francisco Hernández‐Bernal et al.|Research Square|2020Cited by 0